Pipeline Outreach Azitra is a clinical stage biotech focused on precision dermatology with lead programs ATR-12 and ATR-04 using engineered S. epidermidis strains. Potential sales opportunity: partner or license discussions with specialty dermatology clinics, rare skin disease networks, and biopharma seeking novel microbiome-based therapies.

Rare Disease Focus ATR-12 targets Netherton syndrome and ATR-04 addresses EGFR inhibitor–associated skin toxicity. Engaging rare disease patient advocacy groups, investigators, and payer programs could unlock indications for orphan dermatology markets and early-access collaborations.

Clinical Execution As a clinical stage entity with ongoing preclinical and presentations at ASGCT and BIO events, there are opportunities to sponsor or co-develop trials, expand investigator-sponsored studies, and leverage thought leadership to attract clinical trial partners.

Financial Readiness With revenue in the mid single digits and substantial funding, Azitra has capital to pursue partnerships, joint ventures, or milestone-based collaborations. Target biotech players and CROs seeking growth opportunities in dermatology-focused microbiome therapies.

Technology & IP Proprietary engineered microbial platform and a library of about 1,500 strains present licensing or collaboration opportunities for cosmetic, cosmeceutical, or adjacent dermatology applications, including the new protein and peptide programs announced at BIO.